4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Prostate Cancer by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 2589 ongoing clinical trials involving Prostate Cancer
Of the 2589 trials,753 trials are in Phase III
Furthermore, 649 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Prostate Cancer by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Prostate Cancer, an oncology condition. The largest number of ongoing clinical trials for Prostate Cancer is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Prostate Cancer-related drug trials.

National Cancer Institute US: The leading ongoing Prostate Cancer related clinical trial sponsor

National Cancer Institute US is the top sponsor for Prostate Cancer-related ongoing clinical trials.

University of Texas MD Anderson Cancer Center, Johnson & Johnson, Memorial Sloan Kettering Cancer Center, and Sidney Kimmel Comprehensive Cancer Center are among other notable clinical trial sponsors involved in Prostate Cancer. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Prostate Cancer

Enzalutamide (Xtandi), Abiraterone acetate (Zytiga), and Olaparib (Lynparza) are among the key marketed drugs involving Prostate Cancer.

Enzalutamide (Xtandi) is a phenylimidazolidine derivative, acts as anti-neoplastic agent. It functions via Androgen Receptor (Dihydrotestosterone Receptor or Nuclear Receptor Subfamily 3 Group C Member 4 or DHTR or NR3C4 or AR) Antagonist mechanism of action. It is formulated as soft gelatin capsules and tablets for oral route of administration. Enzalutamide is marketed for the treatment of Prostate Cancer and several other indications including Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hormone-Sensitive Prostate Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, and Metastatic Prostate Cancer. Enzalutamide was first approved in 2012 and is marketed globally including the US, France, Germany, China, and Japan by several pharma giants including Astellas Pharma Inc, and PT Meprofarm.

Abiraterone acetate (Zytiga) is an antineoplastic agent. It functions via Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 1.14.14.32) Inhibitor mechanism of action. It is formulated as tablets and film coated tablets for oral route of administration. Zytiga is indicated in combination with prednisone for the treatment of metastatic prostate cancer (castration-resistant prostate cancer) in patients who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in patients who have received prior chemotherapy containing docetaxel after failure of androgen deprivation therapy and in combination with prednisone for the treatment of patients with metastatic high-risk castration-sensitive prostate cancer. Abiraterone acetate was first approved in 2011 and is marketed globally including the US, France, Germany, China, and Japan by Johnson & Johnson.